Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06178159 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 1, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Enrollment target: 80 to 40 Primary completion date: Dec 2024 to Jun 2026 · Completion date: Jun 2025 to Dec 2026v3 Show 2 more changesShow less
    • Primary completion date: Dec 2024 to Jun 2026
    • Completion date: Jun 2025 to Dec 2026
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 2023 to Nov 28, 2023 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Dec 2023 to Nov 28, 2023
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin in combination with Pertuzumab with or without Toripalimab neoadjuvant therapy in patients with HER2-positive breast cancer.
Trial Details
NCT Number NCT06178159
Lead Sponsor RemeGen Co., Ltd.
Conditions Breast Cancer
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov